[Pharmacological properties of the new neuroleptic of the phenothiazine series--dixyrazine].
D000200:Action Potentials / Q000187:drug effects; D000661:Amphetamine / Q000037:antagonists & inhibitors; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D001058:Apomorphine / Q000037:antagonists & inhibitors; D001341:Autonomic Nervous System / Q000187:drug effects; D001464:Barium / Q000037:antagonists & inhibitors; D001775:Blood Circulation / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects; D002746:Chlorpromazine / Q000494:pharmacology* / Q000633:toxicity; D003214:Conditioning, Classical / Q000187:drug effects; D003864:Depression, Chemical; D004357:Drug Synergism; D004597:Electroshock; D005730:Ganglionic Blockers / Q000494:pharmacology; D006168:Guinea Pigs; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D066298:In Vitro Techniques; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009132:Muscles / Q000494:pharmacology; D009949:Orientation / Q000187:drug effects; D010433:Pentylenetetrazole / Q000494:pharmacology; D010640:Phenothiazines / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D012018:Reflex / Q000187:drug effects; D012119:Respiration / Q000187:drug effects; D012702:Serotonin Antagonists; D012890:Sleep / Q000187:drug effects; D013565:Sympatholytics / Q000494:pharmacology; D014149:Tranquilizing Agents / Q000494:pharmacology* / Q000633:toxicity; D014839:Vomiting / Q000517:prevention & control
D000927:Anticonvulsants; D005730:Ganglionic Blockers; D006634:Histamine H1 Antagonists; D010640:Phenothiazines; D012702:Serotonin Antagonists; D013565:Sympatholytics; D014149:Tranquilizing Agents; D001464:Barium; D000661:Amphetamine; D001058:Apomorphine; D002746:Chlorpromazine; D010433:Pentylenetetrazole
Farmakologicheskie svoĭstva novogo neĭroleptika fenotiazinovogo riada--diksirazina.